Anixa Biosciences Inc (ANIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 10-31. Amounts in USD.

Revenue Annual

0 3.5M 7M 10.5M FY10: 730.7K FY11: 1M FY12: 940K FY13: 388.9K FY14: 3.7M FY15: 9.3M FY16: 300K FY17: 362.5K FY18: 1.1M FY19: 250K FY21: 512K FY23: 210K FY24: 210K FY10 FY12 FY14 FY16 FY18 FY21 FY24

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-15M -10M -5M 0 5M 10M 15M FY10: -5.2M FY11: -5M FY12: -4.1M FY13: -7.9M FY14: -5M FY15: -944.8K FY16: -4.5M FY17: -6.1M FY18: -14.3M FY19: -11.9M FY20: -10M FY21: -13.1M FY22: -13.9M FY23: -11M FY24: -13.8M FY25: -11.7M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-15M -10M -5M 0 5M 10M 15M FY10: -5.2M FY11: -7.4M FY12: -4.3M FY13: -10.1M FY14: -9.6M FY15: -1.4M FY16: -5M FY17: -5M FY18: -14M FY19: -11.6M FY20: -10M FY21: -13M FY22: -13.6M FY23: -9.8M FY24: -12.6M FY25: -10.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-7.5M -5M -2.5M 0 2.5M 5M 7.5M FY10: -2.4M FY11: -716K FY12: -3.1M FY13: -3.2M FY14: -2.4M FY15: 1.4M FY16: -3.4M FY17: -3.8M FY18: -4.3M FY19: -4.7M FY20: -6.2M FY21: -4.9M FY22: -6.5M FY23: -6.2M FY24: -7.3M FY25: -7.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-7.5M -5M -2.5M 0 2.5M 5M 7.5M FY10: -2.4M FY11: -725K FY12: -3.1M FY14: -2.4M FY15: 1.3M FY16: -3.5M FY17: -3.8M FY18: -4.3M FY19: -4.9M FY20: -6.2M FY10 FY11 FY12 FY14 FY15 FY16 FY17 FY18 FY19 FY20

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 10M 20M 30M FY21: 28.6M FY22: 30.4K FY23: 31K FY24: 31.9K FY25: 32.5K FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '11: -0.03 Q3 '11: -0.03 Q4 '11: -0.05 Q1 '12: -0.04 Q2 '12: -0.03 Q3 '12: -0.02 Q4 '12: -0.01 Q1 '13: -0.02 Q2 '13: -0.03 Q3 '13: -0.04 Q4 '13: -0.04 Q1 '14: -0.05 Q2 '14: -0.05 Q3 '14: 0.00 Q4 '14: -0.34 Q1 '15: 0.09 Q2 '15: -0.15 Q3 '15: -0.37 Q4 '15: -16.01 Q1 '16: -16.60 Q2 '16: -16.50 Q3 '16: -16.45 Q4 '16: -0.58 Q1 '17: -0.81 Q2 '17: -0.64 Q3 '17: -0.63 Q4 '17: -0.62 Q1 '18: -0.32 Q2 '18: -0.42 Q3 '18: -0.60 Q4 '18: -0.78 Q1 '19: -0.92 Q2 '19: -0.97 Q3 '19: -0.78 Q4 '19: -0.59 Q1 '20: -0.47 Q2 '20: -0.46 Q3 '20: -0.46 Q4 '20: -0.45 Q1 '21: -0.41 Q2 '21: -0.37 Q3 '24: -0.39 Q4 '24: -0.39 Q1 '25: -0.39 Q2 '25: -0.38 Q3 '25: -0.35 Q4 '25: -0.35 Q1 '26: -0.33 Q2 '26: -0.31 Q4 '12 Q3 '14 Q2 '16 Q1 '18 Q4 '19 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.